HIGHLIGHTS
- Who: Posted Date January and colleagues from the National Taiwan University have published the research work: Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving pangenotypic direct-acting antivirals, in the Journal: (JOURNAL)
- How: The primary endpoint of the study analyzed the diagnostic accuracy of serum HCV RNA level at off-treatment week 4 to predict patients who achieved SVR12 or experienced viral relapse at off-treatment week 12.
SUMMARY
The study`s treatment . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.